Immunoliposome therapy

Last updated

Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes (artificial lipid bilayer vesicles) coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body. [1] The antibody modified liposomes target tissue through cell-specific antibodies with the release of drugs contained within the assimilated liposomes. [1] Immunoliposome aims to improve drug stability, personalize treatments, and increased drug efficacy. [1] This form of therapy has been used to target specific cells, protecting the encapsulated drugs from degradation in order to enhance their stability, to facilitate sustained drug release and hence to advance current traditional cancer treatment. [1]

Contents

History

Alec D. Bangham discovered liposomes in the 1960s as spherical vesicles made of a phospholipid bilayer that houses hydrophilic cores. [2] The liposomes were then studied to uncover the properties of biological membranes and a hydration method was discovered to prepare artificial liposomes from 1968 to 1975. [2] Since then, multiple methods of preparing liposomes have been utilized and their characteristics (physical and chemical) have been studied. [2]

Monoclonal antibodies are proteins that stick to specific antigens that tag specific cells and can be synthesized in the lab. [3] They were first generated in 1975 and have since advanced to being used for immunotherapy. [3]

Immunolipsomes were developed utilizing both of these components. [1] The first anticancer drug made with this method was doxorubicin (DOX) in the 1990s. [4]

Composition and structure

Figure 1. Schematic of a basic Immunoliposome; the antibodies (red Y-shapes) are conjugated to the phospholipids (yellow-green) that encapsulate the drug (pink dots). Figure 1ab.png
Figure 1. Schematic of a basic Immunoliposome; the antibodies (red Y-shapes) are conjugated to the phospholipids (yellow-green) that encapsulate the drug (pink dots).

The core structure of immunoliposomes is a lipid bilayer. This lipid bilayer forms a hydrophilic core, which provides stable encapsulation for a therapeutic payload. [5] Common lipids used are phosphatidylcholine (PC), phosphatidylethanolamine (PE), and cholesterol. [5] The lipid bilayer is surface modified through conjugation using monoclonal antibodies for specific recognition of the target cells or tissues of interest. [5] The core of the immunoliposome contains the therapeutic payload, which can be anything from small drugs, nucleic acids, peptides, or imaging agents. [5]

There are often stabilizers and excipients present for formulation, stability, and functionality. [5] Some include polyethylene glycol (PEG), antioxidants to prevent degradation of lipids, and buffering agents for optimal pH. [5]

Synthesis

Immunoliposomes are created when antibodies are conjugated to liposomes. [6] One way to do this is through covalent bonds between the antibody (or its fragment) and the lipid. [6] Another way is through chemical modification of antibodies so they have a higher affinity for the liposome. [6] “In general, the conjugation methodology is based on three main reactions; a reaction between activated carboxyl groups and amino groups which yields an amide bond, a reaction between pyridyl dithiols and thiols which yields disulfide bonds, and a reaction between maleimide derivatives and thiols, which yields thioether bonds.” [6]

Conjugation via carboxyl and amino residues

Figure 2: Process from which a carboxylate is converted into an unstable, amine reactive product using EDC to help stabilize it. This is then turned directly into amide bond, carboxyl group, or uses reagent, sulfo-NHS, to produce more amide bonds. Figure 3a.png
Figure 2: Process from which a carboxylate is converted into an unstable, amine reactive product using EDC to help stabilize it. This is then turned directly into amide bond, carboxyl group, or uses reagent, sulfo-NHS, to produce more amide bonds.

Amine groups are found throughout an antibody and are used as a target due to their easy steric accessibility and modification. An overview of this reaction is found in Figure 2. Most often amine groups found on lysine are covalently bonded to carboxyl groups of glutamic and aspartic acid on formed liposomes using certain agents. A two step process is utilized where the first step uses 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide to create an amine reactive product from the carboxyl group. [6] This product is a target for a nucleophilic attack by the amine but it hydrolyzes quickly, so EDC is added to stabilize it. As seen in the Figure 2, the intermediate can lead to the desired stable amide bond by chance or the recreation of a carboxyl group. [6] To create more of the desired carboxyl-amine bond, N-hydroxysulfosuccinimide (sulfo-NHS) is added to form another intermediate that is an NHS ester. [6] The second step to this reaction is for the antibodies to use the N-terminus of the lipid to covalently conjugate by creating an amide bond via displacement of sulfo-NHS groups. [6] This leads to the final product of an antibody conjugated to a liposome to create an immunoliposome. This process is highly efficient and effective while maintaining the biological activity of the antibody. [6]

Conjugation via thiol group

Figure 3: The mechanism for antibody-lipid conjugation through a thiol group is shown here using maleimide as the anchor. Figure 4a.png
Figure 3: The mechanism for antibody-lipid conjugation through a thiol group is shown here using maleimide as the anchor.

Another process of creating immunoliposomes is by using a thiol group and creating a thioether bond. [6] The sulfhydryl group is a key player can is found in cysteine bridges on proteins and reagents like Traut’s reagents, SATA, and Sulfo-LC-SPDP. [6] The reduction or hydrolysis of these groups generates thiol groups that create antibody conjugation to lipids. [6] There are multiple methods of this process, and one uses the crosslinking agent SATA as shown in Figure 3. [6] The ester end of SATA reacts with amino groups in proteins to form an amide link and a molecule with a protected sulfhydryl group. [6] In order to continue the reaction, this group must be freed which is done by adding hydroxylamine. The following step is to add a chemical that can be an anchor between the lipid and the thiol group. Some examples of molecules that are capable of being this anchor are maleimide, iodoacetyl groups or 2-pyridyldithiol groups. [6] Ultimately, these steps create an antibody-enzyme conjugate that has been formulated using a thiol group. [6]

Mechanism of action

Immunoliposomes use similar functionality as liposomes with the added measure of conjugating monoclonal antibodies and their fragments to the liposomes. [6] The use of antibodies allow for easy targeting as they can recognize many different types of antigens. [6] Diseased cells typically contain more antigens than healthy cells, which is how antibodies are able to appropriately target certain extracellular domains (depending on antigen overexpression) and kill diseased cells. [6] Liposomal drug delivery combined with antibodies as a targeting ligand are what help immunoliposomes function as an effective drug carrier. [6]

Figure 4: Intravascular cells (left side) vs. extravascular cells (right side) (AI) Figure 5- Intravascular cells (left side) vs. extravascular cells (right side).png
Figure 4: Intravascular cells (left side) vs. extravascular cells (right side) (AI)

Once the immunoliposomes deliver the appropriate drugs to the targeted cells, they can enter the cell using either selective uptake of liposomes by endocytosis or liposome release near the targeted cell. [6] Because of antibody conjunction, the cellular uptake amount is increased for immunoliposomes allowing greater drug entry into diseased cells. [6] To control when a drug is released, immunoliposomes are being developed that can sense stimuli. This stimuli can come from the microenvironment of a tumor using factors such as reduced pH, temperature, and enzyme levels. [6] External stimuli like light, heat, magnetic fields, or ultrasound can also act as a trigger for drug release. [6]

Immunoliposomes can target a wide variety of cell options. This can be split into two main types commonly known as intravascular and extravascular space as seen in Figure 4. [7] Intravascular cells are more accessible during circulation and include erythrocytes, myeloid cells, lymphocytes, neutrophils, etc. [7] Extravascular cells are located on tissue parenchymal or stromal cells. [7] Because immunoliposomes have many antibody copies, they contain a higher avidity than just one antibody alone allowing for effective targeting against cancer cells and some drug resistant cells. [7]

Applications

Immunoliposome applications use its ability to act as a drug delivery system and release specific drug components to target cells. This mechanism can be specifically highlighted in cancer cell targeting and through nutrient delivery systems.

Cancer cell targeting

The most common use of immunoliposomes is to target cancer cells using different antibodies. Folate receptors and transferrin receptors are typically overexpressed on cancer cells , so immunoliposomes will target these corresponding ligands. [8] Folate receptors dictate tumor cell specificity and have been seen to be expressed in multiple inflammatory diseases including psoriasis, Crohn’s disease, atherosclerosis, and rheumatoid arthritis making folate-targeted immunoliposomes an efficient drug carrier to deliver antiinflammatory drugs. [8] Transferrin receptors help with the iron demand in proliferating cancer cells and allow for formation of transferrin receptor-targeted anticancer therapies. [8] EGFR (epidermal growth factor) is a tyrosine kinase receptor overexpressed in solid tumors such as colorectal, non small-cell lung cancer, squamous cell carcinoma, and breast cancer making it another target receptor for immunoliposomes. [8] Some cancers create tumors that have multiple different receptors being overexpressed or utilize cancer stem cells, which allow for differentiation of numerous cancer types, so to combat this, dual-targeting immunoliposomes are being created to target multiple ligands and increase therapeutic efficacy. [9]

Nutrient delivery system

Figure 5: Immunoliposome nutrient delivery system Figure 6a.png
Figure 5: Immunoliposome nutrient delivery system

Immunoliposomes can also be used as nutrient delivery systems to help stimulate brain activity. The effective transport of certain nutrients to the hypothalamus in order to regulate brain activity is currently a huge problem. [10] The leptin gene is used to regulate feedback loops and send signals from the adipose tissue to the hypothalamus. [10] Using this physiological function of leptin, immunoliposome nutrient delivery systems can be integrated into the body to help with nutrition transport to the brain as seen in Figure 5. [10] Transferrin receptors have high expression at the BBB (blood brain barrier) and can be used as targets for immunoliposomes to transport p-glycoprotein substances. [10]

Advantage and limitations

Immunoliposomes have many possible applications as described above and have certain advantages in new research and ideas. [6] Some advantages being researched include immunoliposomes targeting specific molecules in the body. [6] In preclinical testing, they can be environmentally responsive to specific conditions of temperature, pH, enzymes, redox reactions, magnetic energy, and light to release drugs. [6] This conditional ability allows immunoliposomes to focus on specific target areas which can be beneficial for drug delivery. [6] Increased targeting allows the possibility for decreased systemic toxicity while increasing drug concentration at a certain site. [6] Even with this advantage of immunoliposomes, there are some challenges in their application.

The success of immunoliposomes during in vivo testing has been shown by multiple groups including Meeroekyai et al 2023 [11] and animal testing has been successful in groups such as Refaat et al 2022. [12] However, they struggle to thrive in higher level and clinical testing. [6] This challenge stems from the variability and lack of understanding of tumors, pharmacokinetics, and large scale production of immunoliposomes. For example, tumors vary but typically have increased vascular permeability and decreased lymphatic drainage which lead to the EPR effect. EFR is the enhanced permeability and retention effect in which drug carriers depend on but the effect and environment can vary in solid tumors. [13] This varying environment makes it hard to predict how the immunoliposome acts and quantify its pharmacokinetics. [6] Additionally, it has been a concern that the animal models used in preclinical testing will not reflect the same effect in humans. [6] Because of this idea, despite any preclinical success, there is a concern to test in humans due to unknown risks. For environmentally responsive immunoliposomes, more modification and purification steps are required to produce the final product. This increase in complexity for immunoliposomes and their behavior also increases costs. [6] Another challenge to marketability and clinical research is the difficulty of scaling up the production of immunoliposomes. The procedure and use of small quantities in the laboratory make upscaling the production a challenge that has not been focused upon. [6]

Research

Figure 6: Clinical research studies with liposomal delivery systems for cancer therapy Figure 7a.png
Figure 6: Clinical research studies with liposomal delivery systems for cancer therapy

Liposomal medicine research for cancer therapy has increased over the years as an alternative to conventional cancer treatment. [14] There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. [14] One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. [14] Other research areas in liposome combination therapy include photodynamic therapy, photothermal agents, radiotherapy, and gas therapy agents. [14]

A immunoliposome therapy clinical study that was completed was conducted by the Swiss Group for Clinical Cancer Research from 2006 to 2009. [15] The study was a phase II clinical trial that looked at the combination of commercially sold Doxorubicin with bevacizumab, a monoclonal antibody that blocks tumor growth. [15] The therapy was used to treat patients with locally recurrent or metastatic breast cancer. [15] Out of the 43 patients, 16 had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity, according to the study. [15] As a result, the combination therapy demonstrated higher than anticipated toxicity while only having modest therapeutic effect. [15] These results concluded that, although immunoliposome therapy has promise, there is still more research needed before translating into commercial products. [15]

Commercialization

Figure 7: Commercially available liposome medicines for cancer therapy Figure 8a.png
Figure 7: Commercially available liposome medicines for cancer therapy

There are several liposome medicines currently available commercially, which helps set the regulatory pathway for immunoliposome therapies. [14]

As immunoliposome therapy has progressed in research, big market players in pharmaceutical research and manufacturing have invested in the development of these therapies. [14] A relevant example of this is a phase I/II trial that examined the effectiveness of PDS0101 in combination with pembrolizumab, an immune checkpoint inhibitor (sold under the brand name Keytruda). [16] The study is funded by PDS Biotechnology and in partnership with Merck. [17] The purpose of the study is to determine the effectiveness of PDS0101 + pembrolizumab in shrinking tumors in patients with virus-related oropharyngeal cancer tumors in humans. [14] PDS0101 is a peptide-based vaccine that aids in the immune response to kill tumor cells. [14] The study also relies on pembrolizumab monoclonal antibodies to help the body's immune system attack the cancer and interfere with the spread of tumor cells. [14]

Figure 8: Liposome therapies that were terminated after clinical trials Figure 9.png
Figure 8: Liposome therapies that were terminated after clinical trials

Although immunoliposome therapy exhibits clinical and commercial promise, there are several known challenges in the translation from laboratory studies to clinical studies and ultimately to commercialization. [14] One obstacle is that immunoliposome therapy is limited by having a short half-life and retention time once it reaches the tumor microenvironment. [14] Additionally, immunoliposome therapies are often individualized which requires close clinical monitoring and comprehensive evaluation methods. [14] From a biochemical perspective, other challenges that immunoliposome therapies face are drug instability due to the phospholipid bilayer and the known possibility for hepatotoxicity. [14] From a manufacturing perspective, designing liposome drug delivery systems at an industrial scale can present a challenge due to the complexity of these drug release mechanisms and their related biosafety. [14]

Similar approaches

Though immunoliposomes serve as a possible advancement, there are other therapies similar to it that trail on the role of targeted drug delivery systems. [18] One example of such therapy is Immune Polymeric nanoparticles, which are similar to liposomes but consist of small particles composed of biodegradable polymers. [18] These nanoparticles similarly encapsulate drugs and can function to enhance specificity towards targeted diseased cells with peptide ligands. [18] Another type is Targeting Antibody Drug Conjugates, which combine monoclonal antibodies with the cytotoxicity of chemotherapy drugs. [19] This specific type is catered towards cancer cells expressing a specific target antigen. [19] They are well-tolerated by the body as they are biodegradable, eliminating many potential toxicity factors, and proving to be a possible new model for therapeutics. [19]

Related Research Articles

<span class="mw-page-title-main">Liposome</span> Composite structures made of phospholipids and may contain small amounts of other molecules

A liposome is a small artificial vesicle, spherical in shape, having at least one lipid bilayer. Due to their hydrophobicity and/or hydrophilicity, biocompatibility, particle size and many other properties, liposomes can be used as drug delivery vehicles for administration of pharmaceutical drugs and nutrients, such as lipid nanoparticles in mRNA vaccines, and DNA vaccines. Liposomes can be prepared by disrupting biological membranes.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

<span class="mw-page-title-main">Anthracycline</span> Class of antibiotics

Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Enhanced permeability and retention effect</span>

The enhanced permeability and retention (EPR) effect is a controversial concept by which molecules of certain sizes tend to accumulate in tumor tissue much more than they do in normal tissues. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels. VEGF and other growth factors are involved in cancer angiogenesis. Tumor cell aggregates as small as 150–200 μm, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply. These newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestrations, lacking a smooth muscle layer, or innervation with a wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage. All of these factors lead to abnormal molecular and fluid transport dynamics, especially for macromolecular drugs. This phenomenon is referred to as the "enhanced permeability and retention (EPR) effect" of macromolecules and lipids in solid tumors. The EPR effect is further enhanced by many pathophysiological factors involved in enhancement of the extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor, tumor necrosis factor and others. One factor that leads to the increased retention is the lack of lymphatics around the tumor region which would filter out such particles under normal conditions.

<span class="mw-page-title-main">Cationic liposome</span>

Cationic liposomes are spherical structures that contain positively charged lipids. Cationic liposomes can vary in size between 40 nm and 500 nm, and they can either have one lipid bilayer (monolamellar) or multiple lipid bilayers (multilamellar). The positive charge of the phospholipids allows cationic liposomes to form complexes with negatively charged nucleic acids through ionic interactions. Upon interacting with nucleic acids, cationic liposomes form clusters of aggregated vesicles. These interactions allow cationic liposomes to condense and encapsulate various therapeutic and diagnostic agents in their aqueous compartment or in their lipid bilayer. These cationic liposome-nucleic acid complexes are also referred to as lipoplexes. Due to the overall positive charge of cationic liposomes, they interact with negatively charged cell membranes more readily than classic liposomes. This positive charge can also create some issues in vivo, such as binding to plasma proteins in the bloodstream, which leads to opsonization. These issues can be reduced by optimizing the physical and chemical properties of cationic liposomes through their lipid composition. Cationic liposomes are increasingly being researched for use as delivery vectors in gene therapy due to their capability to efficiently transfect cells. A common application for cationic liposomes is cancer drug delivery.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

<span class="mw-page-title-main">Monoclonal antibody therapy</span> Form of immunotherapy

Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.

<span class="mw-page-title-main">Paclitaxel trevatide</span> Chemical compound

Paclitaxel trevatide is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. Phase II clinical trials have completed for several indications, and the company is preparing for phase III trials.

Folate targeting is a method utilized in biotechnology for drug delivery purposes. This Trojan Horse process, which was created by Drs. Christopher P. Leamon and Philip S. Low, involves the attachment of the vitamin, folate, to a molecule/drug to form a "folate conjugate". Based on the natural high affinity of folate for the folate receptor protein (FR), which is commonly expressed on the surface of many human cancers, folate-drug conjugates also bind tightly to the FR and trigger cellular uptake via endocytosis. Molecules as diverse as small radiodiagnostic imaging agents to large DNA plasmid formulations have successfully been delivered inside FR-positive cells and tissues.

<span class="mw-page-title-main">Antibody–drug conjugate</span> Class of biopharmaceutical drugs

Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.

Photoimmunotherapy (PIT) is an oncological treatment that combines photodynamic therapy of tumor with immunotherapy treatment. Combining photodynamic therapy with immunotherapy enhances the immunostimulating response and has synergistic effects for metastatic cancer treatment.

Directed enzyme prodrug therapy (DEPT) uses enzymes artificially introduced into the body to convert prodrugs, which have no or poor biologically activity, to the active form in the desired location within the body. Many chemotherapy drugs for cancer lack tumour specificity and the doses required to reach therapeutic levels in the tumour are often toxic to other tissues. DEPT strategies are an experimental method of reducing the systemic toxicity of a drug, by achieving high levels of the active drug only at the desired site. This article describes the variations of DEPT technology.

Nanoparticles for drug delivery to the brain is a method for transporting drug molecules across the blood–brain barrier (BBB) using nanoparticles. These drugs cross the BBB and deliver pharmaceuticals to the brain for therapeutic treatment of neurological disorders. These disorders include Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and brain tumors. Part of the difficulty in finding cures for these central nervous system (CNS) disorders is that there is yet no truly efficient delivery method for drugs to cross the BBB. Antibiotics, antineoplastic agents, and a variety of CNS-active drugs, especially neuropeptides, are a few examples of molecules that cannot pass the BBB alone. With the aid of nanoparticle delivery systems, however, studies have shown that some drugs can now cross the BBB, and even exhibit lower toxicity and decrease adverse effects throughout the body. Toxicity is an important concept for pharmacology because high toxicity levels in the body could be detrimental to the patient by affecting other organs and disrupting their function. Further, the BBB is not the only physiological barrier for drug delivery to the brain. Other biological factors influence how drugs are transported throughout the body and how they target specific locations for action. Some of these pathophysiological factors include blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered gene expression and protein synthesis. Though there exist many obstacles that make developing a robust delivery system difficult, nanoparticles provide a promising mechanism for drug transport to the CNS.

Cancer treatments may vary depending on what type of cancer is being targeted, but one challenge remains in all of them: it is incredibly difficult to target without killing good cells. Cancer drugs and therapies all have very low selective toxicity. However, with the help of nanotechnology and RNA silencing, new and better treatments may be on the horizon for certain forms of cancer.

An Immune stimulating antibody conjugate is a monoclonal antibody that conjugates an antibody to an immune-stimulatory agent. They have been used in targeting tumors in mouse models, particularly to turn "cold tumors into hot ones". Immune stimulating antibody conjugates work by activating dendritic cells within the tumor, and are capable of being delivered systemically. With some patients being resistant to checkpoint inhibitors, immune stimulating antibody conjugates may be able to harness an immune response generated through the stimulation of toll-like receptors. In mice models, "dendritic cells (DCs) [were able] to internalize tumor antigens and subsequently activate tumor-reactive T cells"; this has been used "to treat autologous and autochthonous tumors successfully".

Passive antibody therapy, also called serum therapy, is a subtype of passive immunotherapy that administers antibodies to target and kill pathogens or cancer cells. It is designed to draw support from foreign antibodies that are donated from a person, extracted from animals, or made in the laboratory to elicit an immune response instead of relying on the innate immune system to fight disease. It has a long history from the 18th century for treating infectious diseases and is now a common cancer treatment. The mechanism of actions include: antagonistic and agonistic reaction, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC).

Cytokines are polypeptides or glycoproteins that help immune cells communicate to each other to induce proliferation, activation, differentiation, and inflammatory or anti-inflammatory signals in various cell types. Studies utilizing cytokines for antitumor therapies has increased significantly since 2000, and different cytokines provide unique antitumor activities. Cytokines hinder tumor cell development mostly through antiproliferative or proapoptotic pathways but can also interrupt development indirectly by eliciting immune cells to have cytotoxic effects against tumor cells. Even though there are FDA-approved cytokine therapies, there are two main challenges associated with cytokine delivery. The first is that cytokines have a short half-life, so frequent administration of high doses is required for therapeutic effect. The second is that systemic toxicity could occur if the cytokines delivered cause an intense immune response, known as a cytokine storm.

pH-responsive tumor-targeted drug delivery is a specialized form of targeted drug delivery that utilizes nanoparticles to deliver therapeutic drugs directly to cancerous tumor tissue while minimizing its interaction with healthy tissue. Scientists have used drug delivery as a way to modify the pharmacokinetics and targeted action of a drug by combining it with various excipients, drug carriers, and medical devices. These drug delivery systems have been created to react to the pH environment of diseased or cancerous tissues, triggering structural and chemical changes within the drug delivery system. This form of targeted drug delivery is to localize drug delivery, prolongs the drug's effect, and protect the drug from being broken down or eliminated by the body before it reaches the tumor.

<span class="mw-page-title-main">Ligand-targeted liposome</span> Ligand-targeted liposomes for use in medical applications

A ligand-targeted liposome (LTL) is a nanocarrier with specific ligands attached to its surface to enhance localization for targeted drug delivery. The targeting ability of LTLs enhances cellular localization and uptake of these liposomes for therapeutic or diagnostic purposes. LTLs have the potential to enhance drug delivery by decreasing peripheral systemic toxicity, increasing in vivo drug stability, enhancing cellular uptake, and increasing efficiency for chemotherapeutics and other applications. Liposomes are beneficial in therapeutic manufacturing because of low batch-to-batch variability, easy synthesis, favorable scalability, and strong biocompatibility. Ligand-targeting technology enhances liposomes by adding targeting properties for directed drug delivery.

References

  1. 1 2 3 4 5 Paszko E, Senge MO (2012). "Immunoliposomes". Current Medicinal Chemistry. 19 (31): 5239–5277. doi:10.2174/092986712803833362. PMID   22934774.
  2. 1 2 3 Trucillo P, Campardelli R, Reverchon E (September 2020). "Liposomes: From Bangham to Supercritical Fluids". Processes. 8 (9): 1022. doi: 10.3390/pr8091022 . ISSN   2227-9717.
  3. 1 2 "Monoclonal Antibodies and Their Side Effects". www.cancer.org. Retrieved 2024-03-22.
  4. ↑ Liu JK (December 2014). "The history of monoclonal antibody development - Progress, remaining challenges and future innovations". Annals of Medicine and Surgery. 3 (4): 113–116. doi:10.1016/j.amsu.2014.09.001. PMC   4284445 . PMID   25568796.
  5. 1 2 3 4 5 6 Fulton MD, Najahi-Missaoui W (April 2023). "Liposomes in Cancer Therapy: How Did We Start and Where Are We Now". International Journal of Molecular Sciences. 24 (7): 6615. doi: 10.3390/ijms24076615 . PMC   10095497 . PMID   37047585.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Sandeep D, AlSawaftah NM, Husseini G (23 February 2024). "Immunoliposomes: Synthesis, Structure, and their Potential as Drug Delivery Carriers" (PDF). Current Cancer Therapy Reviews -- RapidX. 16 (4): 306–319. doi:10.2174/1573394716666200227095521. hdl:11073/19721 – via RapidX.
  7. 1 2 3 4 Di J, Xie F, Xu Y (2020). "When liposomes met antibodies: Drug delivery and beyond". Advanced Drug Delivery Reviews. 154–155: 151–162. doi:10.1016/j.addr.2020.09.003. PMID   32926944.
  8. 1 2 3 4 Tenchov R, Bird R, Curtze AE, Zhou Q (November 2021). "Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement". ACS Nano. 15 (11): 16982–17015. doi:10.1021/acsnano.1c04996. PMID   34181394.
  9. ↑ Kim JS, Shin DH, Kim JS (January 2018). "Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells". Journal of Controlled Release : Official Journal of the Controlled Release Society. 269: 245–257. doi:10.1016/j.jconrel.2017.11.026. PMID   29162480.
  10. 1 2 3 4 5 Xianghua Y, Zirong X (December 2006). "The use of immunoliposome for nutrient target regulation (a review)". Critical Reviews in Food Science and Nutrition. 46 (8): 629–638. doi:10.1080/10408390500507167. PMID   17092828.
  11. ↑ Meeroekyai S, Jaimalai T, Suree N, Prangkio P (February 2024). "CD4+ T cell-targeting immunoliposomes for treatment of latent HIV reservoir". European Journal of Pharmaceutics and Biopharmaceutics. 195: 114166. doi:10.1016/j.ejpb.2023.12.006. PMID   38110161.
  12. ↑ Refaat A, del Rosal B, Bongcaron V, Walsh AP, Pietersz G, Peter K, et al. (January 2023). "Activated Platelet-Targeted IR780 Immunoliposomes for Photothermal Thrombolysis". Advanced Functional Materials. 33 (4). doi: 10.1002/adfm.202209019 . ISSN   1616-301X.
  13. ↑ Wu J (August 2021). "The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application". Journal of Personalized Medicine. 11 (8): 771. doi: 10.3390/jpm11080771 . PMC   8402171 . PMID   34442415.
  14. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Chen J, Hu S, Sun M, Shi J, Zhang H, Yu H, et al. (February 2024). "Recent advances and clinical translation of liposomal delivery systems in cancer therapy". European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 193: 106688. doi: 10.1016/j.ejps.2023.106688 . PMID   38171420.
  15. 1 2 3 4 5 6 Swiss Group for Clinical Cancer Research (2012-06-26). Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial (Report). clinicaltrials.gov.
  16. ↑ PDS Biotechnology Corp. (2024-03-12). A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection (Report). clinicaltrials.gov.
  17. ↑ "DEVELOPING POWERFUL, SAFE, VERSATILE IMMUNOTHERAPIES". pdsbiotech.com. Retrieved 2024-04-12.
  18. 1 2 3 Liu Q, Wang X, Liu X, Kumar S, Gochman G, Ji Y, et al. (April 2019). "Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model". ACS Nano. 13 (4): 4778–4794. doi:10.1021/acsnano.9b01444. PMC   6506187 . PMID   30964276.
  19. 1 2 3 Shastry M, Gupta A, Chandarlapaty S, Young M, Powles T, Hamilton E (May 2023). "Rise of Antibody-Drug Conjugates: The Present and Future". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 43 (43): e390094. doi:10.1200/EDBK_390094. PMID   37229614.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.